Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Eculizumab→

Eculizumab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
219685-50-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
Complement Inhibitor
Mechanism of action
Complement Inhibitors [MoA]
Indications / reported uses
  • Hemoglobinuria, Paroxysmal
  • Myasthenia Gravis
  • Atypical Hemolytic Uremic Syndrome
  • patients with Shiga toxin E
  • patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Eculizumab Environmental Risk Assessment (ERA) (the Eculizumab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.